New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
July 24, 2014
16:13 EDTTSROTESARO reports Q2 EPS ($1.03), consensus (87c)
TESARO anticipates achieving the following key objectives during the second half of 2014: Submit the oral rolapitant New Drug Application to the FDA in approximately six weeks; Initiate a clinical trial of IV rolapitant to support the planned future NDA submission for registration following regulatory approval of oral rolapitant; Continue to advance the Phase 3 NOVA trial of niraparib as a maintenance therapy for patients with ovarian cancer and the Phase 3 BRAVO trial of niraparib in breast cancer patients with germline BRCA mutations; Advance the TSR-011 controlled release formulation work and further evaluate the clinical activity of a fractionated dose of TSR-011 in ALK-positive and TRK-positive patients.
News For TSRO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
February 23, 2015
06:25 EDTTSROMedivation removed from Focus List at Citigroup
Subscribe for More Information
06:23 EDTTSROCiti ups TESARO price target to $79, adds to focus list
Subscribe for More Information
February 20, 2015
05:53 EDTTSROTESARO price target raised to $50 from $44 at Mizuho
Mizuho raised its price target for TESARO shares to $50 citing increased confidence and market opportunity for niraparib following the company's Q4 results. The firm expects approval for rolapitant in Q3 and reiterates a Buy rating on the stock.
February 19, 2015
16:13 EDTTSROTESARO reports Q4 EPS ($1.33), consensus ($1.03)
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use